SCHEMBL4676089

SCHEMBL4676089

CC(=O)c1ccc(Cc2cscc2C(=O)C=C(O)C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.45
LMNA P02545 2/20 0.44
PTGER4 P35408 1/20 0.37
PTGER2 P43116 1/20 0.37
TSHR P16473 2/20 0.36
HSD17B10 Q99714 1/20 0.35
CYP2C9 P11712 1/20 0.35
TBXAS1 P24557 3/20 0.34
PYCR1 P32322 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 2/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
RXRA P19793 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAOB P27338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676086 1.00 KMT2A (0.45) KMT2ALMNAPTGER4PTGER2TSHR
SCHEMBL4680962 0.87 SRD5A2 (0.37) LMNAPTGER4PTGER2HSD17B10CYP2C9
SCHEMBL4680966 0.87 SRD5A2 (0.37) LMNAPTGER4PTGER2HSD17B10CYP2C9
SCHEMBL4677260 0.85 CYP2C9 (0.41) PTGER4PTGER2TSHRCYP2C9L3MBTL1
SCHEMBL4677257 0.85 CYP2C9 (0.41) PTGER4PTGER2TSHRCYP2C9L3MBTL1
SCHEMBL4671185 0.84 CYP2C9 (0.36) KMT2ALMNAPTGER4PTGER2CYP2C9
SCHEMBL4671187 0.84 CYP2C9 (0.36) KMT2ALMNAPTGER4PTGER2CYP2C9
SCHEMBL4673157 0.84 CYP2C9 (0.36) PTGER4PTGER2TSHRCYP2C9TDP1
SCHEMBL4673159 0.84 CYP2C9 (0.36) PTGER4PTGER2TSHRCYP2C9TDP1
SCHEMBL4674889 0.84 ALDH1A1 (0.40) LMNACYP2C9NPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KMT2A 597/4885LMNA 659/4885PTGER4 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.